2020.06.24

Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Adult T-cell Leukemia/lymphoma in Japan

Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Adult T-cell Leukemia/lymphoma in Japan

Full text

2020.12.16

Chipscreen and HISUN reach a strategic cooperation

Chipscreen and HISUN reach a strategic cooperation

Full text

2020.03.24

Chipscreen Biosciences's Original New Drug CS12192: Investigational New Drug (IND) Application Accepted

Chipscreen Biosciences's Original New Drug CS12192: Investigational New Drug (IND) Application Accepted

Full text

2019.12.03

National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) for Breast Cancer Indication

National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) for Breast Cancer Indication

Full text

2019.10.09

Chipscreen and Novogene enter a strategic partnership for companion diagnostics development

Chipscreen and Novogene enter a strategic partnership for companion diagnostics development

Full text

2019.09.20

Chipscreeen Biosciences’s Original New Drug Bilessglu® (for Type 2 Diabetes): Commercialization Application Accepted

Chipscreeen Biosciences’s Original New Drug Bilessglu® (for Type 2 Diabetes): Commercialization Application Accepted

Full text

2018.05.30

Good News! CHIPSCREEN BIOSCIENCES Is Approved to Be Provincial Engineering Research Center

Good News! CHIPSCREEN BIOSCIENCES Is Approved to Be Provincial Engineering Research Center

Full text

2018.05.19

The CHIPSCREEN BIOSCIENCES was invited to participate in celebration of 40th anniversary of WHO Uppsala Monitoring Center

The CHIPSCREEN BIOSCIENCES was invited to participate in celebration of 40th anniversary of WHO Uppsala Monitoring Center

Full text

2018.04.27

Asian Pharmaceutical Organization Cooperation Conference ( APAC ) and Drug Development Alliance Working Group ( DA-EWG) visits the CHIPSCREEN BIOSCIENCES

Asian Pharmaceutical Organization Cooperation Conference ( APAC ) and Drug Development Alliance Working Group ( DA-EWG) visits the CHIPSCREEN BIOSCIENCES

Full text

2018.04.25

Master core technology and make China's own innovative medicine - Dr. Lu Xianping, the chairman of CHIPSCREEN BIOSCIENCES, won " 2017 China pharmaceutical development award for outstanding achiev

Master core technology and make China's own innovative medicine - Dr. Lu Xianping, the chairman of CHIPSCREEN BIOSCIENCES, won " 2017 China pharmaceutical development award for outstanding achiev

Full text

2018.04.12

Dr. Lu was invited to attend the first global forum of 30 Chinese scientists for innovation and transformation

Dr. Lu was invited to attend the first global forum of 30 Chinese scientists for innovation and transformation

Full text

2018.01.03

Dr. Lu, the president of CHIPSCREEN BIOSCIENCES and the company, were honored with " 2017 Let Love Go Home Project"

Dr. Lu, the president of CHIPSCREEN BIOSCIENCES and the company, were honored with " 2017 Let Love Go Home Project"

Full text

2017.12.13

Innovation leads to future and patents build strength - CHIPSCREEN BIOSCIENCES wins Chinese Patent Gold Award

Innovation leads to future and patents build strength - CHIPSCREEN BIOSCIENCES wins Chinese Patent Gold Award

Full text

2017.11.23

Experts from the adverse reaction monitoring center of the state general administration visited CHIPSCREEN BIOSCIENCES for research

Experts from the adverse reaction monitoring center of the state general administration visited CHIPSCREEN BIOSCIENCES for research

Full text

2017.11.07

The third histone deacetylase inhibitor (HDACi) summit was successfully held in Nanjing

The third histone deacetylase inhibitor (HDACi) summit was successfully held in Nanjing

Full text